RxDoctor Payments Data

Matthew Levinsky, MD

Cardiovascular Disease · Concord, NCNPI 1235172123

Payments from drug & device makers

$615in general payments, 2019–2025

Across 15 payments — averaging $41.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$231
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$195
  • Boston Scientific$151
  • Novartis$22
  • AstraZeneca$17

What the payments were for

  • Food & beverage$57593%
  • Education$417%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$615 in reported general payments places this provider in the 25th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$152,610
Medicare patients
1,654
Services billed
3,171

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban562$499,630
EntrestoSacubitril/Valsartan84$83,580
XareltoRivaroxaban84$73,265
Repatha SureclickEvolocumab53$38,191
JardianceEmpagliflozin12$13,863
Flecainide Acetate230$7,326
Diltiazem 24hr Er (La)Diltiazem Hcl11$3,140
Metoprolol Succinate221$3,019
Diltiazem 24hr Er (Cd)Diltiazem Hcl77$2,907
Atorvastatin Calcium128$1,204
Dofetilide18$1,079
Ranolazine ErRanolazine15$1,022
Carvedilol117$994
Isosorbide Mononitrate ErIsosorbide Mononitrate88$911
Diltiazem 24hr ErDiltiazem Hcl20$814

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$22$83,58084 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Concord

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →